Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder.
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016001:Confidence Intervals; D003586:Cytomegalovirus Infections / Q000150:complications; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D015994:Incidence; D008232:Lymphoproliferative Disorders / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D012189:Retrospective Studies; D012307:Risk Factors; D014180:Transplantation
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3